Colorectal Cancer
By Anne Rowe
A new report released by the American Cancer Society (ACS) shows that the incidence of colorectal cancer is rapidly increasing among younger individuals, and the disease is also being diagnosed at more advanced stages in people of all ages. Read More ›
On January 19, 2023, the FDA accelerated the approval of tucatinib (Tukysa; Seagen), a Bruton tyrosine kinase inhibitor, in combination with trastuzumab (Herceptin), a HER2/neu receptor agonist, for the treatment of RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer (CRC) that progressed after fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies. This combination was granted a breakthrough therapy designation for this indication. Read More ›
Adagrasib (MRTX849), an inhibitor of the KRASG12C mutation, showed encouraging activity as monotherapy and in combination with cetuximab (Erbitux) in patients with metastatic colorectal cancer (CRC) in the phase 1/2 KRYSTAL-1 trial. All patients had metastatic CRC with KRASG12C mutations and had received previous treatment. Read More ›
The following clinical trials represent
a selection of key studies currently
recruiting patients with colorectal
cancer for inclusion in
investigations of new therapies and
new regimens of existing treatments
for the disease. Each clinical trial
description includes the NLM Identifier
to be used as a reference with
ClinicalTrials.gov. This information
can help oncology practice managers
and providers direct eligible patients
to one of these clinical trials. Read More ›
By William King
The first-line immunotherapy combination of nivolumab (Opdivo) and low-dose ipilimumab (Yervoy) continues to show robust, durable clinical benefit, with a deepening of response, in patients with microsatellite instability high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC), according to results presented at the ASCO 2020 virtual annual meeting. Read More ›
There is a new standard of care in the first-line treatment setting for the subset of patients with advanced colorectal cancer (CRC) that is associated with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR), according to data presented at the ASCO 2020 virtual annual meeting. Read More ›
By Wayne Kuznar
The combination of encorafenib (Braftovi) plus cetuximab (Erbitux), with or without binimetinib (Mektovi), improved the quality of life based on patient-reported assessments better than current standard of care in the treatment of patients with metastatic colorectal cancer (CRC) and BRAF V600E mutation, according to the BEACON CRC study, which was presented at the 2020 Gastrointestinal Cancers Symposium.
Read More ›The following clinical trials represent a selection of key studies that are currently recruiting patients with different types of colorectal cancer for inclusion in investigations of new therapies as well as new regimens of existing treatments for patients with colorectal cancer. Read More ›